CITIUS PHARMAC (Germany) Alpha and Beta Analysis

47N Stock  EUR 3.29  0.00  0.00%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as CITIUS PHARMAC DL. It also helps investors analyze the systematic and unsystematic risks associated with investing in CITIUS PHARMAC over a specified time horizon. Remember, high CITIUS PHARMAC's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to CITIUS PHARMAC's market risk premium analysis include:
Beta
0.0681
Alpha
(1.57)
Risk
7.83
Sharpe Ratio
(0.20)
Expected Return
(1.53)
Please note that although CITIUS PHARMAC alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, CITIUS PHARMAC did 1.57  worse than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of CITIUS PHARMAC DL stock's relative risk over its benchmark. CITIUS PHARMAC DL has a beta of 0.07  . As returns on the market increase, CITIUS PHARMAC's returns are expected to increase less than the market. However, during the bear market, the loss of holding CITIUS PHARMAC is expected to be smaller as well. .
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out CITIUS PHARMAC Backtesting, CITIUS PHARMAC Valuation, CITIUS PHARMAC Correlation, CITIUS PHARMAC Hype Analysis, CITIUS PHARMAC Volatility, CITIUS PHARMAC History and analyze CITIUS PHARMAC Performance.

CITIUS PHARMAC Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. CITIUS PHARMAC market risk premium is the additional return an investor will receive from holding CITIUS PHARMAC long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in CITIUS PHARMAC. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate CITIUS PHARMAC's performance over market.
α-1.57   β0.07

CITIUS PHARMAC expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of CITIUS PHARMAC's Buy-and-hold return. Our buy-and-hold chart shows how CITIUS PHARMAC performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

CITIUS PHARMAC Market Price Analysis

Market price analysis indicators help investors to evaluate how CITIUS PHARMAC stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading CITIUS PHARMAC shares will generate the highest return on investment. By understating and applying CITIUS PHARMAC stock market price indicators, traders can identify CITIUS PHARMAC position entry and exit signals to maximize returns.

CITIUS PHARMAC Return and Market Media

The median price of CITIUS PHARMAC for the period between Sun, Sep 15, 2024 and Sat, Dec 14, 2024 is 7.99 with a coefficient of variation of 38.97. The daily time series for the period is distributed with a sample standard deviation of 2.95, arithmetic mean of 7.56, and mean deviation of 2.4. The Stock did not receive any noticable media coverage during the period.
 Price Growth (%)  
       Timeline  

About CITIUS PHARMAC Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including CITIUS or other stocks. Alpha measures the amount that position in CITIUS PHARMAC DL has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CITIUS PHARMAC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CITIUS PHARMAC's short interest history, or implied volatility extrapolated from CITIUS PHARMAC options trading.

Build Portfolio with CITIUS PHARMAC

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Other Information on Investing in CITIUS Stock

CITIUS PHARMAC financial ratios help investors to determine whether CITIUS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CITIUS with respect to the benefits of owning CITIUS PHARMAC security.